29.81
-0.62 (-2.04%)
| Previous Close | 30.43 |
| Open | 30.02 |
| Volume | 429,911 |
| Avg. Volume (3M) | 283,965 |
| Market Cap | 1,492,530,048 |
| Price / Sales | 4.86 |
| Price / Book | 4.13 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | -16.47% |
| Operating Margin (TTM) | -1.67% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 19.80% |
| Quarterly Earnings Growth (YOY) | 864.20% |
| Total Debt/Equity (MRQ) | 119.96% |
| Current Ratio (MRQ) | 4.38 |
| Operating Cash Flow (TTM) | 26.06 M |
| Levered Free Cash Flow (TTM) | 38.39 M |
| Return on Assets (TTM) | -4.08% |
| Return on Equity (TTM) | -14.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Immunocore Holdings plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.5 |
| Average | 0.25 |
|
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.19% |
| % Held by Institutions | 93.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (HC Wainwright & Co., 235.46%) | Buy |
| Median | 50.00 (67.73%) | |
| Low | 33.00 (Mizuho, 10.70%) | Hold |
| Average | 57.80 (93.90%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 27.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 14 Apr 2025 | 50.00 (67.73%) | Buy | 26.92 |
| Needham | 10 Apr 2025 | 71.00 (138.18%) | Buy | 25.82 |
| 12 Mar 2025 | 71.00 (138.18%) | Buy | 29.05 | |
| Mizuho | 07 Apr 2025 | 33.00 (10.70%) | Hold | 26.28 |
| HC Wainwright & Co. | 12 Mar 2025 | 100.00 (235.46%) | Buy | 29.05 |
| 05 Mar 2025 | 100.00 (235.46%) | Buy | 30.25 | |
| Morgan Stanley | 07 Mar 2025 | 35.00 (17.41%) | Hold | 29.80 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 May 2025 | Announcement | Immunocore reports first quarter financial results and provides a business update |
| 02 Apr 2025 | Announcement | Immunocore to present at upcoming investor conferences |
| 10 Mar 2025 | Announcement | Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 |
| 03 Mar 2025 | Announcement | Immunocore to present at upcoming investor conferences |
| 26 Feb 2025 | Announcement | Immunocore reports fourth quarter and full year 2024 financial results and provides a business update |
| 19 Feb 2025 | Announcement | Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |